New perspectives in dendritic cell-based cancer immunotherapy

BioDrugs

Volumn 15, Issue 10, 2001, Pages 667-679

  Nencioni, Alessio ^a   Brossart, Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; CELL TRANSFER; DENDRITIC CELL; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0035171028     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115100-00004     Document Type: Review

References (107)

1. Steinman RM, Lustig DS, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice: III. functional properties in vivo. J Exp Med 1974; 139 (6): 1431-45
2. Banchereau J, Steinmann RM. Dendritic cells and the control of immunity. Nature 1998; 392 (6673): 245-52
3. Steinmann RM. The dendritic cells system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96
4. Brugger W, Brossart P, Scheding G, et al. Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation. Ann N Y Acad Sei 1999; 872: 363-71
5. Caux C, Dezutter-Dembuyant C, Schmitt D, et al. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 55 (6401): 258-61
6. + progenitors that are expanded by c-kit ligand and yield pure dendritic cells colonies in the presence of GM-CSF and TNFa. J Exp Med 1995; 182(4): 1111-20
7. Fisch P, Köhler G, Schaefer HE, et al. Generation of antigen presenting cells for soluble protein antigens ex vivo from peripheral blood CD34 hematopoietic progenitor cells in cancer patients. Eur J Immunol 1996; 26 (3): 595-600
8. Flores-Romo L, Bjork LP, Ouvert V, et al. CD40 ligation on human CD34 progenitors induces their proliferation and differentiation into functional dendritic cells. J Exp Med 1997; 185 (2): 341-9
9. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by GM-CSF plus IL-4 and down regulated by TNFa. J Exp Med 1994; 179(4): 1109-18
10. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83 dendritic cells. Proc Natl Acad Sei USA 1996; 93 (6): 2588-92
11. Brossart P, Grünebach F, Stuhler G, et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40-ligation in the absence of granulocytemacrophage colony-stimulating factor. Blood 1998; 92 (11): 4238-47
12. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811
13. Geissmann F, Prost C, Monnet JP, et al. Transforming growth factor beta 1, in the presence of granulocyte macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med 1998; 187 (6): 961-6
14. Chomarat P, Banchereau J, Davoust J, et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1 (6): 510-4
15. Mekori YA, Metcalfe D. Mast cells in innate immunity. Immunol Rev 2000; 173: 131-40
16. Brossart P, Zobiwalsky A, Grünebach F et al. TNF-a and CD40 ligand antagonize the inhibitory effects of IL-10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 2000; 60 (16): 4485-92
17. Mortarini R, Anichini A, Di Nicola M, et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of Melan-A/MART-1(27-35) specific CTL from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997; 57 (24): 5534-41
18. Arpinati M, Green CL, Heimfeld S, et al. Granulocyte colony-stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95 (8): 2484-90
19. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12: 991-1045
20. Allavena P, Sica A, Vecchi A, et al. The chemokine receptor switch paradigm and dendritic cells migration: its significance in tumor tissues. Immunol Rev 2000; 177: 141-9
21. Sallusto F, Lanzavecchia A. Understanding dendritic cells and T lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177: 134-40
22. Yoshida R, Imai T, Hieshima J, et al. Molecular cloning of a novel human CC chemokine EBIl-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem 1997; 272 (21): 13803-9
23. Regnault A, Lankar D, Lacabanne V, et al. Fc gamma receptor mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189(2): 371-80
24. Maurer D, Fiebiger E, Reininger B, et al. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. J Immunol 1998; 161 (6): 2731-9
25. Castellino F, Boucher PE, Eichelberg K, et al. Receptor mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000; 191 (11): 1957-64
26. Arnold-Schild D, Hanau D, Spehner D, et al. Receptor mediated endocytosis of heat shock proteins by professional antigen presenting cells. J Immunol 1999; 162 (7): 3757-60
27. Singh-Jasuja H, Toes RE, Spec P, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000; 191 (11): 1965-74
28. Brossart P. Goldrath AW, Butz EA, et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997; 158 (7): 3270-6
29. Inaba K, Inaba M, Naito M, et al. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 1993; 178 (2): 479-88
30. Rescigno M, Granucci F, Citterio S. Coordinated events during bacteria-induced DC maturation. Immunol Today 1999; 20 (5): 200-3
31. Moll H. Epidermal Langerhans cells are critical for immunoregulation of cutaneous leishmaniasis. Immunol Today 1993; 14 (8): 383-7
32. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigens from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392 (6671): 86-9
33. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta 5 and CD36 and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188 (7): 1359-68
34. Rubartelli A, Poggi A, Zocchi MR. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the a(v)3 integrin and requires intracellular and extracellular calcium. Eur J Immunol 1997; 27 (8): 1893-900
35. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000; 290 (5489): 92-7
36. Jeanine P, Renno T, Goethsch L, et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 2000; 1 (6): 502-9
37. Salio M, Cerundolo V, Lanzavecchia A. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells. Eur J Immunol 2000; 30 (2): 705-8
38. Gagliardi MC, Sallusto F, Marinaro M, et al. Choiera toxin induces maturation of dendritic cells and licences them from Th2 priming. Eur J Immunol 2000; 30 (8): 2394-403
39. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191 (3): 423-33
40. Ferlazzo G, Semino C, Spaggiari GM, et al. Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell lysates. Int Immunol 2000; 12 (12): 1741-7
41. Basu S, Binder RJ, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-KB pathway. Int Immunol 2000; 12(11): 1539-46
42. Kalinski P, Hilkens CM, Wierenga EA, et al. T cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20 (12): 561-7
43. Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocyte-derived dendritic cells express high levels of interleuldn-12 in response to combined CD40 ligand and interferon-y treatment. Blood 2000; 96 (10): 3499-504
44. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of Thl, Th2 and non-polarized T cells. Nat Immunol 2000; 1 (4): 311-6
45. Stuhler G, Zobywlaski A, Grünebach F, et al. Immune regulatory loops determine productive interactions within human T lymphocytes-dendritic cells clusters. Proc Natl Acad Sei U S A 1999; 96 (4): 1532-5
46. lezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenie stimulation determines the fate of naive and effector T cells. Immunity 1998; 8(1): 89-95
47. Gunzer M, Schäfer A, Borgmann S, et al. Antigen presentation in extracellular matrix: interaction of T cells with dendritic cells are dynamic, short lived and sequential. Immunity 2000; 13 (3): 323-32
48. Brocker T. Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J Exp Med 1997; 186 (8): 1223-32
49. Ludewig B, Oehen S, Barchiesi RA, et al. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J Immunol 1999; 163 (4): 1839-44
50. Yuong JW, Steinman RM. Accessory cell requirements for the mixed leucocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells. Cell Immunol 1988; 111 (2): 167-82
51. Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sei U S A 1990; 87 (19): 7698-702
52. Fong L, Engelman EG. Dendritic cells in cancer immunotherapy. Annu Rev Imunol 2000; 18: 245-73
53. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184 (5): 1953-62
54. Paluka A, Pulendran B, Davoust J, et al. In vivo mobilization of dendritic cell precursors in normal volunteers after Flt3-L administration [abstract]. Blood 1999; 94 Suppl. 1: 379a
55. Morse MA, Nair S, Fernandez-Casal M, et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol 2000; 18 (23): 3883-93
56. Pulendran B, Banchereau J, Burkeholder S, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cells subsets in vivo. 5 Immunol 2000; 165 (l):566-72
57. Gasparetto C, Rooney B, Gasparetto M, et al. Mobilization of dendritic cells from patients with breast cancer using Flt3-ligand and G-CSF or GM-CSF [abstract]. Blood 1999; 94 Suppl. 1: 636a
58. Brossait P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-cell responses in vivo after vaccination with peptide-pulsed dendritic cells. Blood 2000; 96 (9): 3102-8
59. Brossait P, Stuhler G, Flad T, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58 (4): 732-6
60. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193 (2): 233-8
61. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192 (9): 1213-22
62. Lyakh La, Koski GK, Telford W, et al. Bacterial lipopolysaccharide, TNF-tx and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD 14+ monocytes through distinct pathways that activate NFKB. J Immunol 2000; 165 (7): 3647-55
63. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2(1): 52-8
64. Wien YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous tumor cells. Blood 2001; 97 (6): 1750-5
65. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 93 (7): 2411-9
66. Mukherji B, Chakraborty NG. Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sei U S A 1995; 92 (17): 8078-82
67. Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10 (6): 673-9
68. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999; 40 (2): 125-9
69. Morse MA, Deng Y, Coleman D, et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1 )-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing CEA. Clin Cancer Res 1999; 5 (6): 1331-8
70. Thurner B, Haendle I, Rôder C, et al. Vaccination with MAGE3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some métastases in advanced stage IV melanoma. J Exp Med 1999; 190(11): 1669-78
71. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLAA2-restricted T-cell epitopes derived from the MUCI tumor antigen for broadly applicable vaccine therapies. Blood 1999; 93 (12); 4309-17
72. Bocchia M, Bronte V, Colombo MP, et al. Antitumor vaccination: where we stand. Haematologica 2000; 85 ( 11 ): 1172-206
73. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995; 7 (7): 85-96
74. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995; 1 (12): 1297-302
75. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104 (2): 173-80
76. Dhodapkar MV, Krasovsky J, Sleinman RM, et al. Mature dendritic cells boost functionally superior CD8+ T cells in humans without foreign helper epitopes. J Clin Invest 2000; 105 (6): R9-R14
77. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4 (3): 328-32
78. Lau R, Wang F, Jeffery J, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001; 24 (1): 66-78
79. Brossart P, Bevan MJ. Presentation of exogenous protein antigens on major histocompatibility class I molecules by dendritic cells: pathways of presentation and regulation by cytokines. Blood 1997; 90 (4): 1594-9
80. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens via H2 congenic cells which do not crossreact in the cytotoxic assay. J Exp Med 1976; 143 (5): 1283-8
81. Ignatius R, Mahnke K, Rivera M, et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+)T-cell responses in vivo. Blood 2000; 96 (10): 3505-13
82. Kim DT, Mitchell DJ, Brockstedt DG, et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997; 159 (4): 1666-78
83. Naif SK, Hull S, Coleman D, et al. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999; 82(1): 121-4
84. Nair SK, Heiser A, Bockzowsky D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6 (9): 1011-7
85. Thornburg C, Boczkowski D, Gilboa E, et al. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implication for cervical cancer immunotherapy. J Immunother 2000; 23 (4): 412-8
86. Tuting T, Wilson CC, Martin DM, et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Thl-biasing cytokines IL-12 and IFN-tx. J Immunol 1998; 160(3): 1139-47
87. Reeves ME, Royal RE, Lam JS, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996; 56 (24): 5672-7
88. Di Nicola M, Siena S, Bregni M, et al. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. Cancer Gene Ther 1998; 5 (6): 350-6
89. Fields RC, Shimizu K, Mule 11. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sei U S A1998; 95 (l6): 9482-7
90. + killer T cells. JExpMed2001; 193 (3): 405-11
91. Arrode G, Boccaccio C, Lule J, et al. Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells. J Virol 2000; 74 (21): 10018-24
92. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165 (7): 3797-803
93. Russo V, Tanzarella S, Dalerba P, et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sei US A 2000; 97 (5): 2185-90
94. Wolfer J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor-rejection antigens for CTL crosspriming. Nat Med 2001; 7 (3): 297-303
95. Bockzowski D, Nair SK, Nam JH, et al. Induction of tumor immunity and cytotoxic T cell responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60 (4): 1028-34
96. Stuhler G, Waiden P. Recruitment of helper T cells for induction of tumor rejection by cytolytic T lymphocytes. Cancer Immunol Immunother 1994; 39 (5): 342-5
97. Stuhler G, Trefzen U, Waiden P. Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti-tumor cytotoxic T cells. Adv Exp MedBiol 1998:451:277-82
98. Kugler A, Stuhler G, Waiden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6 (3): 332-6
99. Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59 (14): 3340-5
100. Serody JS, Collins EG, Tisch RM, et al. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J Immunol 2000; 164 (9): 4961-7
101. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166 (6): 4254-9
102. Salgaller ML, Thurner M, Bartsch G, et al. Report from the International Union against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials. Cancer 1999; 86: 2674-83
103. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18 (23): 3894-903
104. Holtl L, Rieser C, Papesh C, et al. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal cell cancer [letter]. Lancet 1998; 352 (9137): 1358
105. Holtl L, Rieser C, Papesh C, etal. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161 (3): 777-82
106. Geiger J, Hutchinson R, Hohenkirk L, et al. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000; 356 (9236): 1163-5
107. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61 (3): 842-7